Ninety One UK Ltd Sells 127,048 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ninety One UK Ltd cut its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,184,680 shares of the medical research company’s stock after selling 127,048 shares during the quarter. Edwards Lifesciences accounts for about 1.4% of Ninety One UK Ltd’s portfolio, making the stock its 23rd largest position. Ninety One UK Ltd owned about 1.22% of Edwards Lifesciences worth $531,882,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in EW. Bowman & Co S.C. boosted its position in shares of Edwards Lifesciences by 1.2% during the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after buying an additional 148 shares during the last quarter. Mount Yale Investment Advisors LLC raised its holdings in shares of Edwards Lifesciences by 1.9% in the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after purchasing an additional 162 shares during the last quarter. JFS Wealth Advisors LLC lifted its position in shares of Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 166 shares in the last quarter. Seascape Capital Management boosted its holdings in Edwards Lifesciences by 0.5% during the third quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after purchasing an additional 174 shares during the last quarter. Finally, Cooper Financial Group grew its position in Edwards Lifesciences by 2.8% in the 4th quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock worth $479,000 after purchasing an additional 175 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,000 shares of company stock worth $547,430 in the last three months. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $71.33 on Wednesday. The company has a 50 day moving average of $72.49 and a 200 day moving average of $69.63. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market cap of $42.07 billion, a P/E ratio of 10.29, a P/E/G ratio of 3.72 and a beta of 1.11. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective on the stock. in a research report on Thursday, January 16th. Canaccord Genuity Group raised their target price on Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group increased their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and a consensus target price of $79.19.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.